Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12609346 | 0.92 | ALDH1A1 (0.47) | ALDH1A1HSD17B10BCL2L1MAPK1HPGD | |
| SCHEMBL164357 | 0.92 | ALDH1A1 (0.48) | ALDH1A1HSD17B10BCL2L1MAPK1HPGD | |
| SCHEMBL27455692 | 0.89 | ALDH1A1 (0.46) | ALDH1A1HSD17B10BCL2L1MAPK1HPGD | |
| SCHEMBL27326199 | 0.89 | ALDH1A1 (0.46) | ALDH1A1HSD17B10BCL2L1MAPK1HPGD | |
| Biphenyl SCHEMBL3199503 | 0.89 | ALDH1A1 (0.50) | ALDH1A1HSD17B10BCL2L1MAPK1HPGD | |
| SCHEMBL3893272 | 0.89 | ALDH1A1 (0.46) | ALDH1A1HSD17B10BCL2L1MAPK1HPGD | |
| Biphenyl SCHEMBL16581537 | 0.86 | ALDH1A1 (0.47) | ALDH1A1HSD17B10BCL2L1MAPK1HPGD | |
| SCHEMBL27855749 | 0.84 | ALDH1A1 (0.42) | ALDH1A1HSD17B10BCL2L1MAPK1HPGD | |
| Benzenethiol SCHEMBL7134302 | 0.84 | ALDH1A1 (0.42) | ALDH1A1HSD17B10BCL2L1MAPK1HPGD | |
| Benzenethiol SCHEMBL3902726 | 0.84 | KMT2A (0.39) | ALDH1A1HSD17B10BCL2L1MAPK1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107022329-B | Aqueous adhesive composition and use thereof | 日东电工株式会社 | 2024-05-28 | — | — | CN | disclosed |
| US-20230096721-A1 | METAL-ORGANIC FRAMEWORK WITH CARBOXYLIC ACID ION HAVING TERPHENYL SKELETON AS LIGAND | RIKKYO EDUCATIONAL CORPORATION (JP) | 2023-03-30 | — | — | US | disclosed |
| EP-4112595-A1 | METAL-ORGANIC FRAMEWORK WITH CARBOXYLIC ACID ION HAVING TERPHENYL SKELETON AS LIGAND | Rikkyo Educational Corporation (JP) | 2023-01-04 | — | — | EP | disclosed |
| CN-115151523-A | Metal-organic structure having carboxylate ion having terphenyl skeleton as ligand | 学校法人立教学院 | 2022-10-04 | — | — | CN | disclosed |
| CN-114828999-A | Gas storage materials containing metal-organic structures bound via hydroxamic acids | 学校法人立教学院 | 2022-07-29 | — | — | CN | disclosed |
| US-11267797-B2 | Anticancer agent | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2022-03-08 | — | — | US | disclosed |
| CN-105503699-B | Oxocarbon compound, resin composition containing the same, and filter containing the resin composition | 株式会社日本触媒 | 2021-05-11 | — | — | CN | disclosed |
| US-20200317630-A1 | ANTICANCER AGENT | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2020-10-08 | — | — | US | disclosed |
| US-10689355-B2 | Anticancer agent | Kyoto Pharmaceuticals Industries, Ltd. (JP) | 2020-06-23 | — | — | US | disclosed |
| EP-3153508-B1 | NAPHTHOFURAN DERIVATIVES FOR USE AS ANTICANCER AGENTS | KYOTO PHARMA IND (JP) | 2020-03-18 | — | — | EP | disclosed |
| US-7074798-B2 | Xanthine derivative and DPPIV inhibitor | EISAI CO., LTD (JP) | 2006-07-11 | — | — | US | disclosed |
| EP-1669348-A1 | NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND | Eisai Co., Ltd. (JP) | 2006-06-14 | — | — | EP | disclosed |
| EP-1338595-B1 | Xanthine derivatives as DPP-IV inhibitors | EISAI CO LTD (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-20050277652-A1 | Novel pyridine derivative and pyrimidine derivative | EISAI CO., LTD. (JP) | 2005-12-15 | — | — | US | disclosed |
| US-20050227959-A1 | Heterocyclic compound having oxime group | EISAI CO., LTD. (JP) | 2005-10-13 | — | — | US | disclosed |
| US-20040082570-A1 | Xanthine derivative and DPPIV inhibitor | EISAI CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1338595-A2 | Xanthine derivatives as DPP-IV inhibitors | Eisai Co., Ltd. (JP) | 2003-08-27 | — | — | EP | disclosed |
| EP-1001932-A1 | CONJUGATES OF DITHIOCARBAMATES WITH PHARMACOLOGICALLY ACTIVE AGENTS AND USES THEREFOR | Medinox, Inc. (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999040787-A1 | MODIFIED PHARMACOLOGICALLY ACTIVE AGENTS AND IMPROVED THERAPEUTIC METHODS EMPLOYING SAME | MEDINOX, INC. (US) | 1999-08-19 | — | — | WO | disclosed |
| WO-1998055453-A1 | CONJUGATES OF DITHIOCARBAMATES WITH PHARMACOLOGICALLY ACTIVE AGENTS AND USES THEREFOR | MEDINOX, INC. (US) | 1998-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082570-A1 | Xanthine derivative and DPPIV inhibitor | DPP4, DPP9, DPP7 | ALDH1A1 112/4885HSD17B10 499/4885BCL2L1 3684/4885 |
| US-20200317630-A1 | ANTICANCER AGENT | TP53, NTPCR, NQO1 | ALDH1A1 160/4885HSD17B10 1095/4885BCL2L1 1116/4885 |
| US-20050277652-A1 | Novel pyridine derivative and pyrimidine derivative | HGF, MET, HDGF | ALDH1A1 930/4885HSD17B10 2323/4885BCL2L1 1261/4885 |
| US-11267797-B2 | Anticancer agent | TP53, NTPCR, NQO1 | ALDH1A1 160/4885HSD17B10 1095/4885BCL2L1 1116/4885 |
| US-10689355-B2 | Anticancer agent | TP53, NTPCR, NQO1 | ALDH1A1 160/4885HSD17B10 1095/4885BCL2L1 1116/4885 |
| US-20050227959-A1 | Heterocyclic compound having oxime group | STAT6, HRH4, HRH2 | ALDH1A1 1391/4885HSD17B10 3089/4885BCL2L1 885/4885 |
| US-20230096721-A1 | METAL-ORGANIC FRAMEWORK WITH CARBOXYLIC ACID ION HAVING TERPHENYL SKELETON AS LIGAND | SCO2, SLCO2A1, OXGR1 | ALDH1A1 1091/4885HSD17B10 836/4885BCL2L1 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.